Results 21 to 30 of about 6,308,723 (207)

Minimal D = 4 N $$ \mathcal{N} $$ = 2 supergravity from D = 11: an M-theory free lunch

open access: yesJournal of High Energy Physics, 2019
We present a new consistent truncation of D = 11 supergravity to D = 4 N $$ \mathcal{N} $$ = 2 minimal gauged supergravity, on the seven-dimensional internal Riemannian space corresponding to the most general class of D = 11 solutions with an AdS4 factor
Gabriel Larios, Oscar Varela
doaj   +1 more source

d ie b e s t im m u n g d e r l a n d n u t z u n g im b e l g r a d WALD DURCH DİE FERNERKUNDUNGSVERFAHREN

open access: yesForestist, 1996
Bei dieser A rbeit ist durch die A nw endung LAN DSA T 5-TM Satellitsbild, das im jahr 1. Septem ber 1990 aufgenom m en ist, die L andnutzung des B elgrad W aldes erforscht.
Ayhan KOÇ, Cafer SELİK
doaj   +1 more source

Little strings on D n orbifolds

open access: yesJournal of High Energy Physics, 2017
We explore two classes of 6d N = 1 0 $$ \mathcal{N}=\left(1,0\right) $$ little string theories obtained from type IIA/IIB NS5-branes probing D n singularities.
Joonho Kim, Kimyeong Lee
doaj   +1 more source

The head of the nominal is N, not D: N-to-D Movement, Hybrid Agreement, and conventionalized expressions

open access: yesGlossa, 2020
The DP Hypothesis has recently come under intense criticism (Bruening 2009, Bruening et al. 2018). In the face of this criticism, several responses have been offered. This paper addresses three such responses and shows that they are without force. First,
Benjamin Bruening
doaj   +2 more sources

Correlation functions for $$n\,\bar{D}_{s1}(2460)$$ n D ¯ s 1 ( 2460 ) and $$n\,\bar{D}_{s1}(2536)$$ n D ¯ s 1 ( 2536 )

open access: yesEuropean Physical Journal C: Particles and Fields
We study the interaction of the $$n \bar{D}_{s1}(2460)$$ n D ¯ s 1 ( 2460 ) and $$n \bar{D}_{s1}(2536)$$ n D ¯ s 1 ( 2536 ) systems from the perspective that the $$D_{s1}(2460)$$ D s 1 ( 2460 ) and $$D_{s1}(2536)$$ D s 1 ( 2536 ) states are molecular ...
Breno Agatão   +5 more
doaj   +1 more source

Животниот Ñтил и контрола на хроничните незаразни болеÑти [PDF]

open access: yes, 2018
Non-communicable diseases, also known as modern-life diseases, are the leading cause of morbidity and mortality in the world and in the Republic of Macedonia. The complexity of their occurrence, often associated with multifactorial etiology and lifestyle
СпаÑовÑки (Spasovski), Моме (Mome)   +3 more
core   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

$$d_{N \Omega }$$ d N Ω production in $$\Omega d$$ Ω d scattering process

open access: yesEuropean Physical Journal C: Particles and Fields
In the present work, we propose to investigate the production of $$d_{N \Omega }$$ d N Ω in the $$\Omega ^{-} d \rightarrow p d_{N \Omega }^-$$ Ω - d → p d N Ω - process by utilizing an effective Lagrangian approach, where $$d_{N \Omega }$$ d N Ω is ...
Quan-Yun Guo, Jing Liu, Dian-Yong Chen
doaj   +1 more source

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine   +14 more
wiley   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy